↓ Skip to main content

Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects

Overview of attention for article published in Alzheimer's Research & Therapy, September 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)

Mentioned by

news
2 news outlets

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
82 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects
Published in
Alzheimer's Research & Therapy, September 2015
DOI 10.1186/s13195-015-0143-0
Pubmed ID
Authors

Artur M N Coutinho, Fábio H G Porto, Fabio L S Duran, Silvana Prando, Carla R Ono, Esther A A F Feitosa, Lívia Spíndola, Maira O. de Oliveira, Patrícia H F do Vale, Helio R. Gomes, Ricardo Nitrini, Sonia M D Brucki, Carlos A. Buchpiguel

Abstract

Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosis as compared to amnestic subtypes of MCI (aMCI). Unfortunately, studies investigating biomarker profiles of naMCI are scarce. The study objective was to investigate the regional brain glucose metabolism (rBGM) with [(18)F]FDG-PET and cerebrospinal fluid (CSF) biomarkers in subjects with naMCI as compared to a control group (CG) and aMCI subjects. Ninety-five patients were included in three different groups: naMCI (N = 32), aMCI (N = 33) and CG (N = 30). Patients underwent brain MRI and [(18)F]FDG-PET. A subsample (naMCI = 26, aMCI = 28) also had an assessment of amyloid-β, tau, and phosphorylated tau levels in the CSF. Both MCI groups had lower rBGM in relation to the CG in the precuneus. Subjects with naMCI showed decreased right prefrontal metabolism as well as higher levels of CSF amyloid-β relative to aMCI subjects. While amnestic MCI subjects showed a biomarker profile classically related to MCI due to Alzheimer's disease, naMCI patients illustrated a decrease in both prefrontal hypometabolism and higher CSF amyloid-β levels relative to the aMCI group. These biomarker findings indicate that naMCI is probably a heterogeneous group with similar precuneus hypometabolism compared to aMCI, but additional frontal hypometabolism and less amyloid-β deposition in the brain. Clinical follow-up and reappraisal of biomarkers of the naMCI group is needed to determine the outcome and probable etiological diagnosis.

Mendeley readers

The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Spain 1 1%
Unknown 79 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 17%
Student > Master 12 15%
Student > Ph. D. Student 9 11%
Unspecified 8 10%
Other 6 7%
Other 21 26%
Unknown 12 15%
Readers by discipline Count As %
Medicine and Dentistry 15 18%
Neuroscience 14 17%
Psychology 13 16%
Unspecified 8 10%
Nursing and Health Professions 3 4%
Other 9 11%
Unknown 20 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 November 2015.
All research outputs
#2,137,617
of 22,832,057 outputs
Outputs from Alzheimer's Research & Therapy
#447
of 1,224 outputs
Outputs of similar age
#30,768
of 268,876 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#7
of 11 outputs
Altmetric has tracked 22,832,057 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,224 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.0. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,876 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.